Celldex Therapeutics, Inc.
CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receā¦ read more
Healthcare
Biotechnology
39 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$32.54
Price+1.69%
$0.54
1Y
Price
Market Cap
$2.165b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-557206.7%
EBITDA Margin-524566.7%
Net Profit Margin-448180.0%
Free Cash Flow Margin-557206.7%
EBITDA Margin-524566.7%
Net Profit Margin-448180.0%
Free Cash Flow MarginRevenue
$820k
-45.3%
1y CAGR-40.7%
3y CAGR+17.5%
5y CAGREarnings
-$283.689m
-9.6%
1y CAGR-28.4%
3y CAGR-27.8%
5y CAGREPS
-$4.27
-9.5%
1y CAGR-17.5%
3y CAGR-18.6%
5y CAGRBook Value
$456.226m
$511.254m
Assets$55.028m
Liabilities$1.908m
DebtDebt to Assets
0.4%
-
Debt to EBITDAFree Cash Flow
-$225.961m
-5.8%
1y CAGR-28.6%
3y CAGR-22.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company